The results highlight iQIYI’s ability to sustain growth despite higher content costs, while its AI‑driven efficiencies and rapid overseas expansion position it to compete more aggressively in the global streaming arena.
iQIYI’s modest top‑line growth reflects a broader shift in China’s streaming market, where premium long‑form content remains a key differentiator. By allocating RMB 4 billion to new productions, the platform secured the top viewership share for dramas, reinforcing its brand equity. At the same time, a 48% sequential rise in distribution revenue shows the profitability of leveraging theatrical releases across digital channels, a model that many rivals are still testing. This dual‑track approach helps balance the volatility of advertising spend, which fell 2% as seasonal campaigns tapered.
The company’s aggressive overseas push is equally noteworthy. International membership revenue grew more than 40% year‑over‑year, with markets such as Brazil, Mexico, and Indonesia seeing subscriber bases double. This expansion reduces reliance on the saturated domestic market and taps into higher‑growth regions where streaming penetration is still rising. Coupled with AI‑generated promotional assets—now covering 70% of overseas marketing—iQIYI can scale acquisition costs efficiently, a competitive edge as global players vie for attention in emerging markets.
AI integration extends beyond marketing into production, localization, and user experience. The partnership with Academy‑award winner Peter Pau to launch an AI Center signals a strategic bet on generative tools that cut creative costs and accelerate content pipelines. Meanwhile, asset‑light iQIYI Lab venues blend XR experiences with IP‑driven merchandise, creating new revenue streams beyond the screen. In a regulatory climate that the company describes as supportive, these innovations position iQIYI to monetize its extensive IP portfolio while maintaining cost discipline, a formula that could reshape profitability benchmarks for Chinese streaming giants.
Comments
Want to join the conversation?
Loading comments...